Compare TG Therapeutics Inc (TGTX) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Veritone Inc — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while Veritone Inc trades at $0.56 (market cap $59.46M). The key difference: TG Therapeutics Inc is far larger — about 137.2× Veritone Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Veritone Inc for 12 Days on average.
| TGTX | VERI | |
|---|---|---|
Market Cap | $8.16B | $59.46M |
Volume | 1,735,121 | 15,523,164 |
Sector | Health | Technology |
52-Week High | $59.06 | $8.39 |
52-Week Low | $26.94 | $0.59 |
Typical Hold Time | 16 Days | 12 Days |
Enterprise Value | $8.37B | $94.86M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Veritone (VERI) trades at $0.5851, down 15.36% in the past 24 hours, reflecting significant bearish pressure. The company shows concerning fundamentals with a net income margin of -117.54% and negative ROE of -547.67% for 2025, though it maintains a gross margin of 66.2%. Recent developments include a $15 million equity offering and partnerships with ATP Media and ZeroEyes, while facing securities class action investigations. Technical indicators show mixed signals with bearish moving averages but bullish oscillators.
The outlook remains challenging with persistent losses and negative cash flow from operations, though analyst consensus suggests upside potential with a $3.75 price target. Key risks include ongoing legal scrutiny, execution challenges in achieving profitability, and competitive pressures in the AI solutions space. The stock presents high-risk speculative potential for investors betting on turnaround execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
